HomeDrug ClassesRNA Splicing Modifiers

RNA Splicing Modifiers: Uses, Common Brands, and Safety Info

"RNA splicing modifiers are a class of medications that target gene expression by modulating the process of RNA splicing. They show potential in treating genetic disorders such as spinal muscular atrophy and Duchenne muscular dystrophy. Common brands include Nusinersen and Ataluren. Safety considerations include mild side effects and ongoing research to determine long-term safety."

RNA Splicing Modifiers

RNA splicing modifiers are a class of medications that target the process of RNA splicing, which is an essential step in gene expression. RNA splicing is responsible for removing non-coding regions (introns) from the pre-messenger RNA (pre-mRNA) molecule and joining the remaining coding regions (exons) together to produce mature, functional mRNA. By modulating this splicing process, RNA splicing modifiers can regulate gene expression and potentially correct abnormalities associated with certain genetic disorders.


RNA splicing modifiers have shown promise in the treatment of various genetic conditions caused by splicing defects. Some of these conditions include:

  • Spinal muscular atrophy (SMA): SMA is a neurodegenerative disorder caused by mutations in the survival motor neuron (SMN1) gene. RNA splicing modifiers can help promote the inclusion of exon 7 in the SMN2 gene, which produces functional SMN protein and improves muscle function.

  • Duchenne muscular dystrophy (DMD): DMD is a genetic disorder characterized by progressive muscle weakness and degeneration. RNA splicing modifiers can target exon skipping, aiming to restore the correct reading frame in the dystrophin gene and potentially slow disease progression.

  • Various genetic cancers: Modifying the splicing patterns of certain genes involved in cancer development and progression may offer exciting therapeutic opportunities.

Common Brands

While the development of RNA splicing modifiers is still in its early stages, some common brands that have emerged include:

  • Nusinersen (Spinraza): Approved for the treatment of spinal muscular atrophy, Nusinersen targets the SMN2 gene splicing to increase the production of functional SMN protein.

  • Ataluren (Translarna): Although not an RNA splicing modifier per se, Ataluren promotes read-through of premature stop codons in certain genetic disorders by affecting the splicing process.


As with any medication, the safety of RNA splicing modifiers should be carefully considered. Common side effects include injection site reactions, fever, and headache, although serious adverse effects are rare. It is essential to consult with a healthcare professional before starting any treatment with these medications, as they may interact with other drugs or have specific contraindications in certain patient populations.

Furthermore, since RNA splicing modifiers are relatively new in the field of medicine, ongoing research is being conducted to evaluate their long-term safety and efficacy.

Overall, RNA splicing modifiers represent an exciting area of therapeutic innovation, with the potential to address genetic conditions by targeting the underlying splicing defects. Through modulating the splicing process, these medications aim to restore or improve the production of functional proteins, offering hope for patients and transforming the landscape of genetic medicine.

List of RNA Splicing Modifiers